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Mild traumatic brain injury (mTBI) disproportionately affects military service members
and is very difficult to diagnose. To-date, there is currently no blood-based, diagnostic
biomarker for mTBI cases with persistent post concussive symptoms. To examine
the potential of neuronally-derived (NDE) and astrocytic-derived (ADE) exosome cargo
proteins as biomarkers of chronic mTBI in younger adults, we examined plasma
exosomes from a prospective longitudinal study of combat-related risk and resilience,
marine resiliency study II (MRSII). After return from a combat-deployment participants
were interviewed to assess TBI exposure while on deployment. Plasma exosomes
from military service members with mTBI (mean age, 21.7 years, n = 19, avg. days
since injury 151), and age-matched, controls (deployed service members who did not
endorse a deployment-related TBI or a pre-deployment history of TBI; mean age,
21.95 years, n = 20) were precipitated and enriched against a neuronal adhesion
protein, L1-CAM, and an astrocyte marker, glutamine aspartate transporter (GLAST)
using magnetic beads to immunocapture the proteins and subsequently selected by
fluorescent activated cell sorting (FACS). Extracted protein cargo from NDE and ADE
preparations were quantified for protein levels implicated in TBI neuropathology by
standard ELISAs and on the ultra-sensitive single molecule assay (Simoa) platform.
Plasma NDE and ADE levels of Aβ42 were significantly higher while plasma NDE and
ADE levels of the postsynaptic protein, neurogranin (NRGN) were significantly lower in
participants endorsing mTBI exposure compared to controls with no TBI history. Plasma
NDE and ADE levels of Aβ40, total tau, and neurofilament light (NFL), P-T181-tau,
P-S396-tau were either undetectable or not significantly different between the two
groups. In an effort to understand the pathogenetic potential of NDE and ADE cargo
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proteins, neuron-like cultures were treated with NDE and ADE preparations from TBI
and non-TBI groups. Lastly, we determined that plasma NDE but not ADE cargo
proteins from mTBI samples were found to be toxic to neuron-like recipient cells
in vitro. These data support the presence of markers of neurodegeneration in NDEs
of mTBI and suggest that these NDEs can be used as tools to identify pathogenic
mechanisms of TBI.
Keywords: traumatic brain injury, neuronal exosomes, astrocytes, amyloid, tau
INTRODUCTION
Traumatic brain injury (TBI) is a global public health concern.
Epidemiological data suggests approximately 10 million people
worldwide will sustain a TBI each year (Hyder et al., 2007).
This is likely a gross underestimation as many mTBI cases
go unreported, especially amongst sports athletes and military
service members (Langlois et al., 2006). Approximately 75% of
all TBI cases are mild TBI (mTBI) or concussions (Holm et al.,
2005; Langlois et al., 2006). mTBI typically results in short-lived,
neurological impairment that resolves spontaneously within
12 months (Binder, 1986; Karr et al., 2014). However, 5–20% of
mTBI cases experience chronic, post concussive symptoms long
after the injury (Ponsford et al., 2011; Karr et al., 2014; Eme,
2017). The underestimation of reported head injury cases and the
chronic sequelae of TBI signifies the need for better diagnostic
tools and therapeutic interventions for head injury patients.
Mild TBI diagnosis is complicated by the lack of
interdisciplinary consensus regarding what constitutes a mTBI
(Kulbe and Geddes, 2016; Prince and Bruhns, 2017). Because
of this, the current criteria for mTBI can be difficult to assess in
patients with pre-existing neurological conditions, intoxicated
patients, and children (Kulbe and Geddes, 2016). In military
populations, the recognition of mTBI is further complicated
by the delay in diagnosis due to lengthy deployments (Marion
et al., 2011). Many mTBI diagnoses are primarily based on the
subjective nature of patients self-reporting mTBI symptoms and
are likely to not be assessed until months or years after the initial
impact (Kulbe and Geddes, 2016; Prince and Bruhns, 2017).
The current state of mTBI diagnostics includes expensive
neuroimaging modalities (Lee and Huang, 2014; Shin et al.,
2017) and cerebral spinal fluid (CSF) sampling (Agoston et al.,
2017). Post concussive symptomology is insensitive to current
neuroimaging techniques while CSF sampling is invasive and
imposes an additional health risk to the patient. The urgent
need to identify pre-symptomatic, neuropathological changes in
the brain at earlier and more treatable timepoints has fueled
research into biofluid biomarkers, specifically those obtained
from plasma and serum. Extensive research has identified
number of promising blood-based and CSF biomarkers of
head injury including tau, neurofilament (NF), glial fibrillary
acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase
isoenzyme L1 (UCHL1), neuron-specific enolase (NSE), myelin
basic protein (MBP), and calcium-binding protein (s100β).
Many of these markers demonstrate high diagnostic accuracy
for the acute stages of severe TBI (Agoston et al., 2017; Kim
et al., 2018) while GFAP has recently emerged as demonstrating
high diagnostic accuracy in differentiating mTBI patients from
controls (Bogoslovsky et al., 2017). Work from our lab and others
demonstrated the utility of neuronally derived, plasma exosomes
(NDEs) as biomarkers for elucidating the neurodegenerative
stages of AD and other diseases (Fiandaca et al., 2015; Goetzl
et al., 2016a, 2018a; Hamlett et al., 2016; Stern et al., 2016;
Winston et al., 2016; Ngolab et al., 2017). However, limited
research has been conducted to assess the diagnostic potential
of blood-based exosomes as a measurement of acute and chronic
sequelae of mTBI (Gill et al., 2018; Goetzl et al., 2018c, 2019).
The acute and chronic sequelae of mTBI involves the
activation of a diverse cascade of pathophysiological processes
and events (DeKosky et al., 1998; Povlishock and Katz, 2005).
Axonal damage, disruption of cytoskeletal networks along with
the redistribution of neurofilament proteins are all thought
to be the primary determinant of outcome following mTBI
(Shahim et al., 2018) and severe TBI (Hamberger et al., 2003;
Johnson et al., 2013). Because of this, many biofluid biomarker
studies target cytoskeletal proteins including the microtubule
stabilizing protein, tau and Neurofilament light (NFL). NFL
is neuron specific, cytoskeletal protein found in myelinated
axons. Axonal damage liberates tau and NFL from axons
and releases it into the CSF and blood (Lin et al., 2018).
Several longitudinal and prospective cohort studies support
serum NFL as an ultrasensitive biomarker for mTBI, sports-
related, repeat concussion (Shahim et al., 2017, 2018) and AD
(Lin et al., 2018). Moreover, tau and phosphorylated epitopes
of tau (p-tau) has been detected immediately after severe
TBI (Tsitsopoulos and Marklund, 2013); plasma tau has been
reported to be increased in military populations approximately
12 months after TBI (McKee et al., 2009; Rubenstein et al.,
2015); and abnormal p-tau accumulation can be detected in post
mortem brain many years after head injury (McKee et al., 2013;
Tsitsopoulos and Marklund, 2013).
Neuroinflammation is also a well characterized pathological
hallmark of head injury (Karve et al., 2016). Astrocytes, one of the
major resident glial cells in the brain, were once thought to only
provide structural support in the central nervous system (CNS)
(Montgomery, 1994). Today, there is a greater appreciation for
the diverse role that astrocytes play in the healthy CNS and
following CNS insult and disease (Karve et al., 2016; Xiong
et al., 2018). Previously, exosomes derived from astrocytes
(ADEs) contained proteins associated with the generation of
the toxic Aβ42 peptide (Goetzl et al., 2016b) and complement
proteins that were associated with neurotoxic reactive astrocytes
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(Goetzl et al., 2018b; Winston et al., 2019). Similarly, cargo
proteins of plasma ADEs accurately differentiated AD patients
from age-matched controls (Goetzl et al., 2016b) and were found
to be predictive biomarker of MCI conversion to AD (Goetzl
et al., 2018b; Winston et al., 2019).
To examine NDE and ADE cargo proteins as biomarkers of
chronic mTBI, we leveraged plasma samples from the Marine
Resiliency Study II (MRSII), a prospective study of combat-
related neurocognitive outcomes in 1,040 Marine and Navy
service members (Glenn et al., 2017). Participants were assessed
at pre-deployment and again at 4–6 months after returning from
a combat deployment to Afghanistan for mental and physical
health and cognitive performance. In the current study, we used
plasma samples from 39 participants of this cohort (controls,
n = 20; mTBI, n = 19), to isolate exosomes.
Exosomes were enriched by magnetic-bead immunocapture
against the neural adhesion marker, L1CAM and the astrocytic
marker, glutamine aspartate transporter (GLAST). Subsequently,
all BAE (bead-antibody-exosome) preparations were FACS
sorted. Protein cargo from NDE and ADE preparations were
extracted, followed by quantitative determination of TBI-related
markers via human specific ELISAs. The markers chosen were
Aβ42, Aβ40, NFL, total tau, phosphorylated tau epitopes,
T181 and S396, and calmodulin-binding, postsynaptic protein
neurogranin (NRGN).
Absorption of NDE cargo from other neurodegenerative
disorders are toxic to receipt cells in vivo (Winston et al., 2018),
however, the pathogenic potential of plasma NDE and ADE cargo
proteins from TBI samples has yet to be investigated. Lastly, we
determined if cargo proteins from NDEs and ADEs were toxic to
recipient cells in vitro.
MATERIALS AND METHODS
Baseline Characteristics of Study
Participants
Participants in this study, a subset of MRS-II participants,
were all male, with a mean age at pre-deployment of 21.87
(SD = 2.76). On average assessments were given at 4 weeks
(SD = 4.9) prior to deployment and again at 22 weeks
(SD = 22.4) following deployment (Marine Resiliency Study
II; Moore et al., 2017). MRS-II TBI assessment methodology
mirrored that of MRS, which assessed life-time head injury (up
to a maximum 5) at pre-deployment, and combat-related head
injuries, defined as any head injury sustained between the pre-
and post-deployment assessments (Yurgil et al., 2014). Detailed
MRS methodology has been reported elsewhere (Baker et al.,
2012); only descriptions of measures relevant to the present study
are presented here. Demographic information (age, ethnicity,
race) was collected via self-report surveys before deployment
and was included in analysis as potential covariates. Head
injury events were assessed via interview before deployment
and after deployment. Interviewers gathered details of each
reported injury, including injury cause or mechanism and
symptom severity. TBI was defined as any head injury that
resulted in loss of consciousness (LOC) or altered mental status
(i.e., dazed, confused, or seeing stars, and/or posttraumatic
amnesia (National Center for Injury Prevention and Control,
2003; von Holst and Cassidy, 2004; Helmick et al., 2006).
Any head injury resulting in LOC and/or altered mental state
(AMS; i.e., dazed, confused, “seeing stars,” and/or posttraumatic
amnesia [PTA]) was defined as TBI (National Center for Injury
Prevention and Control, 2003; O’Neil et al., 2014; Yurgil et al.,
2014). For this study we selected post-deployment plasma
samples from participants who self-reported multiple (2+)
head injuries during the index deployment (n = 17 mean age,
21.74 ± 0.9; average number of TBI, 2.526 ± 0.1772, average
number of days between most recent deployment TBI and
sample collection 151 ± 112 days). In the TBI exposed group,
94% reported at least one injury that involved LOC, with the
majority (82%) experiencing LOC < 15 min. Although the
utility of neuroimaging has improved for mTBI diagnoses (Salat
et al., 2017) imaging was not conducted on these participants.
Moreover, no participant endorsed an injury with fracture or
head wound. At the time of sample collection participants
were asked if they were experiencing any current problems
from the TBI, including memory problems, balance problems,
headaches, sensitivity to light, irritability, and/or sleep problems.
94% endorsed experiencing at least one current symptom
(average number of symptoms endorsed 3 ± 1.5). 76% of
participants endorsed a blast/explosion-related TBI. Trauma-
and deployment-exposed controls who did not endorse a history
of TBI were selected for similarities in age, ethnicity/race, #
of months in the military and range of trauma-symptoms as
assessed by the Clinician Administered PTSD Symptom Scale
(CAPS, version for DSM-IV) (Blake et al., 1995). The CAPS is
a structured interview that is considered the gold standard for
assessment of PTSD symptom severity. At the time of assessment,
blood was drawn into EDTA-treated tubes, after which plasma
was isolated for storage in −80◦C freezers. See Demographics
Table 1 for details.
This study was approved by the institutional review boards
of the University of California, San Diego; the Veterans Affairs
San Diego Research Service; and the Naval Health Research
TABLE 1 | Demographics, military, and TBI history.
No history of TBI TBI
Age (years) 22.0 ± 1.2 21.7 ± 0.7
Race/Ethnicity 70% Caucasian,
5% African American,
15% Hispanic,
10% Asian/Other
71% Caucasian,
6% African American,
12% Hispanic,
11% Asian/Other
# Months in military 36.5 ± 12.1 32.9 ± 9.8
PTSD symptoms 23.25 ± 25 35.11 ± 25
Deployment stress 0.27 ± 0.61 0.79 ± 0.63∗
Average # of TBI 0 2.59 ± 0.8
Measures are means ± SD. PTSD Symptoms assessed by Clinician Administered
PTSD Symptom Scale for DSM-IV (Blake et al., 1995). Deployment Stress
assessed using the Deployment Risk and Resiliency Inventory (variable is based on
a composite score across four scales: post-battle experiences, combat experience,
deployment concern, difficult living, and working environment (Vogt et al., 2013).
∗p < 0.05 vs. No history of TBI group, t34 = −2.55.
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Center and written informed consent was obtained from
all participants.
Enrichment of Neuronal-Derived (NDEs)
and Astrocyte-Derived Exosomes (ADEs)
From Human Plasma via Bead Antibody
Exosome (BAE) – FITC Complex and
FACS Sort
Exosome isolation was conducted per manufacturer’s
instructions (System Biosciences, Inc., Mountain view, CA,
United States; Catalog # EXOQ5TM-1). Briefly, 250 µL of
human plasma were incubated with 2.5 µL purified thrombin
(System Biosciences, Inc.; Catalog # TMEXO-1) at room
temperature for 5 min. After centrifugation at 10,000 rmp for
5 min, supernatants were incubated with 63 µL ExoQuick
Exosome Precipitation solution (System Biosciences, Inc.;
Catalog # EXOQ5TM-1) for 30 min at 4◦C. Resultant
suspensions were centrifuged at 1,500 × g for 1 h at 4◦C.
Supernatant was collected and the resultant pellet was suspended
in 300 µL of 1× phosphate buffer saline (PBS) (diluted from
10× PBS; Thermo Fisher Scientific; Catalog# AM9625) with Halt
protease and phosphatase inhibitor cocktail EDTA-free (Thermo
Fisher Scientific; Catalog # 78443) and stored at −80◦C until
immunochemical enrichment of exosomes from both neural and
astrocytic sources.
Neural and astrocyte enrichment was conducted per
manufacturer’s instructions (System Biosciences, Inc.; Catalog
# CSFLOWBASICA-1). Briefly, 40 µL of 9.1 µm, streptavidin
magnetic Exo-Flow beads (System Biosciences, Inc.; Catalog
# CSFLOWBASICA-1) were incubated with 100 ng/µL of
mouse anti-human CD171 (L1CAM, neural adhesion protein)
biotinylated antibody (clone 5G3, eBioscience/Thermo Fisher
Scientific; Catalog # 13-1719-82) or mouse anti-human GLAST
(ACSA-1) biotinylated antibody (Miltenyi Biotec, Inc., Auburn,
CA, United States; Catalog # 130-118-984) for 2 h on ice,
with gently flicking every 30 min to mix. Bead-antibody (Ab)
complex was washed three times in Bead Wash Buffer (Systems
Biosciences, Inc.; CSFLOWBASICA-1) using a magnetic stand.
Bead-Ab complex was suspended with 400 µL of Bead Wash
Buffer and 100 µL of total exosome suspensions rotating
overnight at 4◦C. Bead-Ab-exosome (BAE) complex was washed
three times with Bead Wash Buffer then suspended in 240 µL of
Exosome Stain Buffer and 10 µL of Exo-FITC Exosome FACS
stain (Systems Biosciences, Inc.; Catalog # CSFLOWBASICA-1)
for 2 h on ice, with gently flicking to mix. BAE-FITC complex
was washed Three times in Bead Wash Buffer then suspended
in 300 µL of Bead Wash Buffer prior to loading into BD FACS
Aria II for sorting.
Flow-sorted, BAE-FITC complexes were incubated with
300 µL of Exosome elution buffer (System Biosciences, Inc.;
Catalog # CSFLOWBASICA-1) at 25◦C for 30 min. Finally,
supernatant containing eluted exosomes were incubated with
1 µL of Exo-FlowIP clearing reagent (System Biosciences,
Inc.; Catalog # EXOFLOW32A) at 37◦C for 30 min then
stored at−80◦C.
Quantification of NDE and ADE Protein
Cargo by Human-Specific Enzyme
Linked Immunosorbent Assays (ELISAs)
and Using the Single Molecule Array
(Simoa) Technology
Protein concentrations for eluted NDE and ADE suspensions
were determined using the Pierce bicinchoninic acid (BCA)
Protein Assay kit (Thermo Fisher Scientific; Catalog # 23225).
Mammalian protein extraction reagent (M-PER) (Thermo Fisher
Scientific; Catalog # 78501) with protease and phosphatase
inhibitors are mixed with eluted NDE and ADE suspensions prior
to ELISA quantification.
L1CAM-positive (NDE) cargo proteins and GLAST-positive
(ADE) cargo proteins were quantified by human-specific
ELISAs for P-T181-tau (Fujirebio US, Inc., Alpharetta, GA,
United States; Catalog # 81582), Aβ1–42 (Cusabio, American
Research Products, Waltham, MA, United States; Catalog
# CSB-E10684h), P-S396-tau (Life Technologies/Invitrogen,
Camarillo, CA, United States; Catalog # KHB7031), neurogranin
(Cloud Clone Corp., American Research Products-Katy, TX,
United States; Catalog # CEA404Hu), and tetraspanning
exosome marker CD81 (Cusabio, American Research Products,
Waltham, MA, United States; Catalog # CSB-EL004960HU) with
verification of the CD81 antigen standard curve using purified
human recombinant CD81 antigen (Origene Technologies, Inc.,
Rockville, MD, United States; Catalog # TP317508), according to
suppliers’ directions. The mean value for all determinations of
CD81 in each assay group was set at 1.00, and the relative values
for each sample were used to normalize their recovery.
Neurofilament light, Aβ40 and total tau were measured
using the Single Molecule Array (Simoa) technology (Simoa;
Quanterix, Lexington, MA, United States) which enables
detection of these biomarkers in human plasma, serum, CSF and
enriched exosomes. The Simoa Human NF-Light Advantage kit
(NFL) (Catalog # 103400) was used to determine the amount of
NFL. The Simoa Human Neurology 3-Plex “A” (3-Plex) (Catalog
# 101995) was used to quantitatively determine the amount of
Ab42, Ab40, and Tau. Tests were performed to optimize dilution
factors and centrifugation. 4× dilution factor was found to be
suitable for the samples. After thawing, the samples were vortexed
and spun at 10,000 g for 5 min; the supernatant was directly
transferred to a 96 well plate (90 µL for singlet or 125 µL
for duplicate). For NFL, a recombinant NFL calibration curve
was constructed and transferred to the 96 well plate (334 µl).
Calibration curve range was 0–500 pg/mL and with the dynamic
range of 0–2000 pg/mL. Control samples (analog 200 pg/mL
and digital 10 pg/mL) and inter-assay control (pooled normal
plasma) were all transferred to the 96 well plate (90 µL for
singlet or 125 µL for duplicate). The 96 well plate was loaded
onboard and the desired dilution factor for the samples was
created by the Simoa HD-1 analyzer. Utilizing a Two-step
procedure in a reaction cuvette, samples were incubated with
antibody coated paramagnetic beads and biotinylated antibody
detector simultaneously. After a wash, streptavidin-conjugated
β-galactosidase (SBG) reagent was added binding the biotinylated
antibodies leading to SBG enzyme labeling of the captured
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NFL. After a second wash, the beads were re-suspended in
resorufin β-D-galactopyranoside (RGP) reagent, transferred to a
Simoa disk array and sealed. The NFL proteins captured by the
antibody coated paramagnetic beads and labeled with the SBG
reagent hydrolyze the RGP substrate to produce a fluorescence
signal (Abs/Em = 573/585 nm). The fluorescent signal values
generated from the calibration curve of known concentrations
were fit using a 4-parameter logistic curve and 1/y2 weighting.
The unknown samples and control samples concentrations were
calculated from 4PL curve fit. Lower Limit of Detection of
NFL was reported at 0.038 pg/mL and the Lower Limit of
Quantification at 0.174 pg/mL.
Multiplexed detection of Aβ40 and total tau was accomplished
by labeling beads with dyes of various wavelengths and
concentrations creating distinct subpopulations of beads.
Antibodies for each specific protein were immobilized to these
color-encoded beads. Mixture of these beads were incubated with
each sample generating detection of multiple proteins. From
the materials provided, a recombinant 3-Plex calibration curve
was constructed and transferred to the 96 well plate (334 µl).
Calibration ranges for Aβ42, Aβ40, and total tau was 0–60,
0–140, and 0–100 pg/mL and dynamic ranges of 0–240, 0–560,
and 0–400 pg/mL, respectively. Aβ40 and total tau control
samples (analog 87.0, 393, and 99.5 pg/mL and digital 3.20, 22.4,
and 2.24 pg/mL, respectively) and inter-assay control (pooled
normal plasma) were all transferred to the 96 well plate (90 µL
for singlet or 125 µL for duplicate). The 96 well plate was loaded
onboard and the desired dilution factor for the samples was
created by the Simoa HD-1 analyzer. A two-step process in a
reaction cuvette was used and samples were incubated with
antibody coated paramagnetic beads and biotinylated antibody
detector simultaneously. After a wash, streptavidin-conjugated
β-galactosidase (SBG) reagent was added binding the biotinylated
antibodies leading to SBG enzyme labeling of the captured Aβ40
and total tau. After a second wash, the beads were re-suspended
in resorufin β-D-galactopyranoside (RGP) reagent, transferred to
a Simoa disk array and sealed. Aβ40 and total tau captured by the
antibody coated paramagnetic beads and labeled with the SBG
reagent hydrolyze the RGP substrate to produce a fluorescence
signal (Abs/Em = 573/585 nm). As with NFL the fluorescent
signal values generated from the calibration curve of known
concentrations were fit using a 4-parameter logistic curve and
1/y2 weighting. The sample and control concentrations were
calculated from 4PL curve fit. Lower limit of detection for Aβ40
and total tau was reported at 0.196 and 0.019 pg/mL, respectively,
and the lower limit of quantification for Aβ40 and total tau was
reported at 0.675 and 0.063 pg/mL, respectively.
Differentiation and Exosome Treatment
of PC12 Cells and Human
Neuroblastoma SH-SY5Y Cells
PC12 cells were cultured in a 5% CO2 humidified atmosphere
at 37◦C. Cells were cultured in PDL-coated Sarstedt plastic T75
tissue culture flasks in DMEM supplemented with 10% horse
serum and 5% fetal bovine serum. For exosome treatment, cells
were transferred to poly-D-lysine (PDL)-coated, Olympus flat
bottom, 12-well plates and plated at a density of 14,000 cells/well.
Differentiation was induced by culturing cells in serum free
media and 50 ng/ml NGF. After 48 h, PC12 cells showed signs
of differentiation that included neurite sprouting. NDEs and
ADEs preparations (100 ng/mL) from control and TBI samples
were applied to NGF + PC12 cells and incubated for 48 h.
Following the experiment, phase contrast images of PC12 cells
were collected using a Nikon digital camera attached to a Zeiss
Axiovert 35 microscope. Subsequently, cell culture media was
collected and stored at−20◦C.
Human neuroblastoma SH-SY5Y cells were maintained and
differentiated as previously described (Kim et al., 2015). Briefly,
cells were maintained in MEM:F12 + 10% FBS and incubated
at 37◦C in 5% CO2. For differentiation, cells were plated on rat
tail collagen coated glass cover slips in MEM:F12 + 3% FBS
supplemented with 15nM retinoic acid. Cells were refed every
2 days for 7 days for complete differentiation. NDEs preparations
from control, TBI, and AD samples (100 ng/mL) were applied to
SH-SY5Y cells and incubated for 48 h. Following the experiment,
cell culture media was collected and stored at−20◦C.
Homogeneous Membrane Integrity
Assay
CtyoTox-ONETM Homogeneous Membrane Integrity Assay was
performed per manufactures instructions (Promega Corporation,
Madison, WI, Catalog # G7890). Briefly, cell culture media from
NDE and ADE-treated NGF + PC12 cells and SH-SY5Y cells
were incubated with 2 µL of Lysis solution (per 100 µL original
volume) for 25 min at 22◦C and then aliquoted, in triplicate, into
a 96 well assay plate. Equal volume of CytoTox-ONETM Reagent
(100 uL) was added to each well containing cell culture media and
incubated at 22◦C for 10 min. 50 µL of stop solution was added
prior to measuring fluorescent intensity at 562 nm using the
iMarkTM Microplate Absorbance Reader (Bio-Rad Laboratories,
Hercules, CA, United States).
Statistical Analyses
Statistical significance of differences between means for cross-
sectional groups mTBI and control were determined with
an unpaired, non-parametric Mann–Whitney t-test (Prism 6;
GraphPad Software, La Jolla, CA, United States). Receiver
operating characteristic (ROC) analyses were conducted to assess
the sensitivity of exosome cargo proteins in distinguishing among
the two patient groups (Prism 6; GraphPad Software). ROC
analyses were conducted under the non-parametric distribution
assumption for standard error of area to determine the
performance of classifier models (SPSS v21.0, IBM).
RESULTS
Validating Neural and Astrocytic
Enrichment of NDEs and ADEs From
Human Plasma Using FACS Analysis
A bead-antibody-exosome (BAE) – FITC complex was generated
to enrich for neuronally derived (NDEs) and astrocyte derived
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(ADEs) exosomes from human plasma (Figure 1A). Mouse
anti-human CD171 (L1CAM) or GLAST (ACSA-1) biotinylated
antibody was coupled to magnetic streptavidin beads followed by
the binding of plasma exosomes isolated from matched young,
healthy military service members with no history of TBI and
service members endorsing > 1 combat-related mTBI events
within the past 4–6 months. The resultant BAE complex was
coupled to a FITC fluorescent tag that only binds to exosomes
(Exo-FITC, System Biosciences Inc.) and subsequently sorted
based green fluorescent intensity. As a negative control, the
resultant non-exosome, bead – antibody – FITC (BA – FITC)
complex was sorted to confirm Exo-FITC secondary antibody
only binds to exosomes (Figure 1B).
Fluorescent activated cell sorting analysis demonstrated that
less than 0.5% of the particles are FITC-positive in the non-
exosome, negative controls (BA-FITC) (Figure 1B) while the
exosome preparations derived from control and TBI groups
(Figure 1B) were between 76.4 and 99.8% Exo-FITC-positive
(n = 19–20/group). The significant degree in flow separation
from the non-exosome control demonstrates flow cytometry is an
efficient method for validating neural and astrocytic enrichment
of NDEs and ADEs from human plasma. The number of FITC
positive (FITC+) events were quantified. We determined that
the recovery of NDEs and ADEs following FACS were not
significantly different between service members with mTBI and
those with no TBI history (Figure 1C). Resultant exosome
preparations were confirmed by ELISA against the exosome
membrane protein marker, CD81 (Figure 1D). Similarly, plasma
NDE levels for CD81 were not statistically different between the
two patient populations (Figure 1D).
Plasma NDE and ADE Levels of Aβ42 Are
Increased While Plasma NDE and ADE
Levels of NRGN Are Decreased in Young
Service Members With Multiple mTBI
Compared to Service Members With No
TBI History
Previously, we reported plasma NDE levels of Aβ42, P-tau-
T181, P-tau-S396 increased while plasma NDE levels of NRGN
FIGURE 1 | Fluorescent activated cell sorting (FACS) enrichment of plasma NDEs from service members with and without mTBI during deployment. Schematic
cartoon of FACS enrichment via the formation of a bead-antibody-exosome (BAE) – FITC complex (A). Representative FACS plot for non-exosome, negative control
(red) and BAE – FITC complexes exosomes (green) isolated from control subject, 12207 (age: 22) and mTBI subject, 11541 (age: 21) and enriched against
anti-human CD171 biotin (L1CAM) or anti-GLAST antibody (B). Total number of FITC+ events were not significantly different between the two populations (C;
114719 ± 3712 FITC+ events vs. 116121 ± 4969 FITC+ events). Plasma NDE and ADE concentrations of exosome marker, CD81 were not statistically different
between the two populations as measured by standard ELISA (D).
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decreased in MCI (mean age, 68.7 years) and AD (71.1 years)
patients as compared to age-matched controls (mean age,
70.8 years) (Winston et al., 2016, 2019). Here, we observed that
plasma NDE and ADE levels of Aβ42 (Figure 2A, P < 0.05) were
significantly increased and levels of NRGN (Figure 2B, P< 0.05)
were significantly decreased in mTBI samples as compared to
age matched controls with no TBI history. Plasma NDE and
ADE levels of P-T181-tau were not significantly different between
the two groups (Figure 2C). Plasma NDE levels of P-S396-tau
were not significantly different between the two groups while
plasma ADE levels of P-S396-tau were elevated in the mTBI
group as compared to controls, however, these data failed to reach
significance (Figure 2D). Across groups, ADE cargo showed
higher levels of Aβ42 (Table 2, 1.18 pg/mL ADEs vs. 0.29 pg/mL
NDEs) and P-396-tau (Table 2, 16.26 pg/mL ADEs vs. 5.47 pg/mL
NDEs) compared to plasma NDE cargo. All NDE and ADE
concentrations for biomarkers analyzed were normalized against
CD81 (Figure 1D).
Quantitative determination of NDE cargo proteins on the
Simoa platform revealed plasma NDE levels of Aβ40 (Figure 3A),
NFL (Figure 3B), and total tau (Figure 3C) were not significantly
different between the two patient populations while plasma ADE
levels Aβ40, total tau, and NFL were negligible or undetectable on
the Simoa platform.
Plasma NDE Cargo Protein From Service
Members With mTBI Are Toxic to
Recipient Cells in vitro
Lastly, we determined the pathogenic potential of plasma NDE
and ADE cargo protein in vitro. The neuronal-like characteristics
of differentiated PC12 cells are well documented (Greene and
Tischler, 1976) and serve as an excellent in vitro model system
for the study of neuronal function and survival. Differentiated
PC12 cells (NGF + PC12 cells) were incubated with 100 ng/mL
of NDE or ADE preparations for 48 h (averaged triplicates;
n = 4 individual samples/group). Exosome-induced cytotoxicity
was assessed by measuring the amount of lactate dehydrogenase
(LDH) released into the cell culture media. LDH is a soluble
protein that is found in all living cells. The release of LDH into
the surrounding media is a result of compromised membrane
integrity and a marker of cell death.
After 48 h, wells treated with plasma NDEs from mTBI
individuals displayed overt signs of cytotoxicity. Representative
FIGURE 2 | Human plasma NDE and ADE levels Aβ1–42 and NRGN differentiate young mTBI individuals from individuals with no TBI history. Plasma NDE and ADE
(A) concentrations of Aβ42 were significantly higher, whereas plasma NDE and ADE (B) concentrations of NRGN were significantly lower in young individuals with
mTBI (n = 17) compared to age-matched controls (n = 20). Plasma NDE and ADE concentrations of P-T181-tau (C), and P-S396-tau (D) were not significantly
different between the two groups. Non-parametric t-test, ∗P < 0.05 vs. control.
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TABLE 2 | Plasma NDE and ADE protein quantification as measured by ELISA and the Sioma platform.
NDE – Hu ELISA ADE – Hu ELISA
Protein Cargo Control pg/ml ± S.E.M. mTBI pg/ml ± S.E.M Protein Cargo Control pg/ml ± S.E.M. mTBI pg/ml ± S.E.M
Aβ42 0.11 ± 0.02 0.48 ± 0.10∗ Aβ42 0.88 ± 0.17 1.49 ± 0.22∗
NRGN 25.13 ± 3.49 15.45 ± 2.16∗ NRGN 50.77 ± 11.92 24.74 ± 5.11∗
P-T181-tau 13.10 ± 0.60 11.97 ± 0.49 P-T181-tau 9.93 ± 0.39 10.32 ± 0.40
P-S396-tau 5.48 ± 0.81 5.45 ± 0.68 P-S396-tau 14.22 ± 1.86 18.30 ± 2.27
NDE – Quanterix Simoa ADE – Quanterix Simoa
Protein Cargo Control pg/ml ± S.E.M. mTBI pg/ml ± S.E.M Protein Cargo Control pg/ml ± S.E.M. mTBI pg/ml ± S.E.M
Aβ40 0.99 ± 0.19 0.75 ± 0.18 Aβ40 0 0
Total Tau 1.55 ± 0.17 1.69 ± 0.18 Total Tau 0.13 ± 0.01 0.12 ± 0.01
NFL 1.47 ± 0.17 1.57 ± 0.14 NFL 0.02 ± 0.01 0.02 ± 0.01
Quantitative determination of NDE and ADE cargo proteins were conducted using an unpaired, non-parametric Mann–Whitney t-test. Plasma NDE and ADE concentrations
of Aβ42 were significantly higher, whereas plasma NDE and ADE concentrations of NRGN were significantly lower in young individuals with mTBI (n = 17) compared to
age-matched controls (n = 20). ∗P < 0.05. Cross sectional analysis revealed that plasma concentrations of ADE cargo (control + mTBI) were significantly higher for Aβ42
(1.18 pg/mL ADEs vs. 0.29 pg/mL NDEs, P < 0.05) and P-396-tau (16.26 pg/mL ADEs vs. 5.47 pg/mL NDEs; P < 0.01) as compared to plasma concentrations of NDE
cargo (control + mTBI).
photomicrographs depicted signs of dendritic blebbing,
suppressed neurite outgrowth, and cell death (Figure 4A).
Compared to controls (100% viability), there was approximately
threefold (286.7%) increase in exosome-induced cytotoxicity in
wells that were treated with NDEs derived from mTBI individuals
(Figure 4B, P < 0.05).
Next, we aimed to replicate our findings in a different in vitro
model system. Differentiated human neuroblastoma SH-SY5Y
cells were treated with 100 ng/mL NDE or ADE preparations
for 48 h (averaged triplicates; n = 4 samples/group). Treatment
of SH-SY5Y cells with plasma NDE preparations from patients
diagnosed with AD was included as a positive control. Again, we
observed approximately threefold (265.8%) increase in exosome-
induced cytotoxicity in wells that were treated with NDEs
derived from samples of service members with mTBI. In wells
that were treated with NDEs derived from AD patients, we
observed approximately fourfold (450.3%) increase in exosome-
induced cytotoxicity as compared to NDEs derived from controls
(Figure 4C, P < 0.05). Interestingly, plasma ADE cargo proteins
from service members with mTBI did not induce cytotoxicity or
compromise the membrane integrity of NGF + PC12 cells or
SH-SY5Y cells (Figures 4B,C).
Together, these data suggest that plasma NDE cargo proteins
from individuals exposed to multiple recent (within 4–6 months)
mTBI events are toxic to neuron-like cells in vitro. Furthermore,
plasma exosomes from different cell types mediate divergent
biological processes in the CNS.
DISCUSSION
In the current study, we report, for the first time, that plasma
NDE and ADE levels of Aβ42 and NRGN can differentiate
military service members with mTBI from those with no TBI with
moderate sensitivity and accuracy (see ROC analysis, Table 3).
Because of the matched control strategy these differences are
unlikely to be due to age, race/ethnicity, # months in military
or PTSD symptoms. Plasma NDE and ADE levels of Aβ42
were significantly increased (Figure 2A) while plasma NDE and
ADE levels of NRGN (Figure 2B) were significantly decreased
in the group with combat-related mTBI, as compared to those
without mTBI. Plasma ADE levels of P-S396-tau were elevated
in the mTBI group as compared to controls, however, these
findings failed to reach significance (Figure 2D). Interestingly,
plasma NDE and ADE levels of Aβ40, P-T181-tau, total tau,
and NFL were either undetectable or not significantly different
between the two groups.
Given that TBI can initiate the abnormal accumulation of Aβ
and tau (Tsitsopoulos and Marklund, 2013), it was surprising
to see that plasma NDE and ADE levels of total tau, P-T181-
tau, P-S396-tau were not significantly different between the two
groups. Surprisingly, cross sectional analysis revealed that total
plasma concentrations of ADE cargo (control + mTBI) were
significantly higher for Aβ42 (see Table 2; P < 0.05) and P-
396-tau (see Table 2; P < 0.01) as compared to total plasma
concentrations of NDE cargo (control + mTBI). It’s not well
understood why total levels of for Aβ42 and P-396-tau were
higher in ADEs as compared to NDEs. Studies have demonstrated
that astrocytes undergo phagocytosis in response to damaged
neighboring cells (Liddelow and Barres, 2017; Wakida et al.,
2018). Thus, its plausible that injury induced accumulation of
Aβ42 and P-396-tau activated a phagocytic response in astrocytes.
This response could result in higher levels of said proteins
within astrocytes that are subsequently exocytosed and trafficked
to the periphery via ADEs. Future studies include determining
how exosome biogenesis and function differ between various
cell populations.
Here, we detect changes in protein levels contained within
exosomes. However, many of the previous studies reported
elevated levels of Aβ42, total tau and p-tau in serum and/or
CSF. One recent study reported elevated levels of exosomal p-tau
and total tau in individuals who sustained > 3 mTBI injuries
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FIGURE 3 | Plasma NDE levels of Aβ40, total tau, and NFL are not significantly different between individuals with and without mTBI. Plasma NDE levels of Aβ40 (A),
NFL (B), and total tau (C), were not significantly different between the two populations while plasma ADE Aβ40 (A), NFL (B), and total tau (C) were not detectable by
the Simoa Assay.
as compared to healthy controls and to those who sustained
2 or fewer mTBIs (Kenney et al., 2018). Interestingly, Kenney
et al. (2018) reported Aβ42 and Aβ40 were undetectable in
total exosomes derived from military veterans and controls.
Gill et al. (2018) extracted NDEs from plasma and reported
tau, Aβ42 and IL-10 were elevated in military servicemembers
who had a mTBI and experienced a LOC of 20 min or
less. In each of these studies, including the current study,
biomarker quantification was assessed in patients with varying
injury severity (mild to moderate); the number of self-
reported mTBI varied amongst the study participants; some
participants reported LOC while others did not; and the
source of biomarker quantification also varied (total exosomal
content vs. NDEs/ADEs). Understanding how all of these
factors impact the expression of various TBI-related, exosome
cargo proteins in the blood will aid in developing better
mTBI diagnostics, prognostics, and would further elucidate
mTBI pathophysiology.
Retrospective cohort studies confirm the relationship between
age, injury severity, and outcome following TBI (LeBlanc
et al., 2006). The age of onset is likely another factor that
impacts the utility of blood-based, exosome biomarkers for
mTBI. Our study participants were 10–20 years younger
than the aforementioned studies (Gill et al., 2018; Kenney
et al., 2018) and upward of 40–50 years younger than
study participants of other exosome-related, biomarker studies
(Fiandaca et al., 2015; Winston et al., 2016, 2019). It’s not
fully understood why certain proteins are packaged into
exosomes and trafficked into the periphery, however, the
temporal profile of blood-based biomarkers may vary across
different age groups. Exosomes are known to shuttle cargo,
including proteins and micro RNA (miRNA) between cells
and aid in the removal of excess or damaged, intracellular
proteins and their cellular contents (Rajendran et al., 2006;
Kalani et al., 2014; Budnik et al., 2016). However, the basic
mechanisms behind exosome transport and function in the
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FIGURE 4 | Plasma NDE cargo from individuals with mTBI compromise membrane integrity and are toxic to neuron-like cells in vitro. Differentiated PC12 cells and
SH-SY5Y cells were incubated with 100 ng/ml of NDE and ADE for 48 h. Representative photomicrographs indicate exosome-induced cytotoxicity. Signs of
cytotoxicity include dendritic blebbing (indicated by arrows), suppressed neurite outgrowth and cell death in NGF + PC12 cells (A). Compared to controls (100%
viability), there was a threefold increase in exosome-induced cytotoxicity (LDH release) in wells that were treated with NDEs derived from service members with mTBI
(B), ∗P < 0.05 vs. control, dashed horizontal line represents 100% viability. SH-SY5Y cells were treated with NDE and ADE preparations from control and mTBI
service members and AD patients. A similar level of cytotoxicity was observed in cultured SH-SY5Y. A threefold increase in exosome-induced cytotoxicity (LDH
release) was observed in wells that were treated with NDEs derived from mTBI samples and a fourfold increase exosome-induced cytotoxicity in wells that were
treated with NDEs derived from AD samples as compared to NDEs derived from control samples (C). Non-parametric t-test; ∗P < 0.05 vs. control, dashed
horizontal line represents 100% viability.
healthy and diseased CNS are still unknown (Hessvik and
Llorente, 2018). In order to enhance the clinical utility
of exosomes in therapy and diagnosis, it is essential that
we gain a better understanding of these cellular processes
(Hessvik and Llorente, 2018). Moreover, creating a profile with
age-appropriate NDE and ADE biomarkers will also enhance
the diagnostic and prognostic utility of blood-based exosome
biomarkers for mTBI.
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TABLE 3 | Receiver Operating Curve analysis for biomarker sensitivity for cargo proteins measured by standard ELISA.
NDE ADE
Protein cargo Sensitivity (% ±SEM) Confidence interval (%) Protein cargo Sensitivity (% ±SEM) Confidence interval (%)
A042 84.6 ± 0.7 70.1–98.4 Aβ42 69.4 ± 0.08 51.8–87.1
NRGN 74.4 ± 0.9 55.1–93.7 NRGN 71.1 ± 0.09 53.9–88.1
The risk of developing of chronic traumatic encephalopathy
(CTE) is a growing concern for military personnel and sports
athletes (Randolph et al., 2013; Chauhan, 2014; Tartaglia et al.,
2014). CTE is a slowly progressing neurodegenerative disease
that typically affects those who suffer repeat mTBI over extended
periods of time. CTE is a clinically and neuropathologically
distinct tauopathy that can only be diagnosed post mortem
(McKee et al., 2009). The ultimate concern, especially in younger
patients, is continued exposure of repeat-mTBI during the
latency period. Identifying blood-based, exosome biomarkers
for mTBI would also serve is useful prognostic biomarkers for
the progression of mTBI to CTE (Stern et al., 2016). Recently,
Goetzl et al. (2019) quantified NDE cargo proteins in young
sports athletes (mean age, 20.67 years) who sustained repeat-
mTBI acutely (7 days) and chronically (3–12 months) prior to the
time of blood donation. They determined plasma NDE levels of
Aβ42 and P-T181-tau were elevated in acute and chronic mTBI
patients while plasma NDE levels of P-S396-tau were elevated
only in chronic mTBI patients as compared to controls (Goetzl
et al., 2019). These data suggest that the diagnostic potential
of the blood-based, exosome cargo proteins, Aβ42 and p-tau,
are sensitive to varying inter-injury intervals (latency period
between mTBI). In our study, blood collection occurred 4–
6 months after the service members returned from deployment.
These differences may also help explain why we didn’t observe a
significant difference in plasma NDE and ADE levels of p-tau and
total tau between the two patient populations.
Interestingly, we observed no difference in plasma NDE
levels of NFL between the two patient groups despite numerous
studies suggesting serum and CSF NFL is a highly sensitive
biomarker for concussion (Shahim et al., 2017, 2018). Shahim
et al. (2017) reported levels of serum NFL levels were elevated
between 7–10 days after a bout in young amateur boxers
(mean age, 21.5 years), however, after 3 months of rest, serum
NFL levels were significantly decreased in the amateur boxers
(Shahim et al., 2017). Although, very few studies have quantified
NFL in exosomes (Kawata et al., 2018), it’s likely that NFL
may only serve as an acute biomarker for mTBI. Plasma
ADE levels of NFL (and Aβ40) derived from the two groups
were undetectable. It’s plausible that the release of NFL from
the neuronal cytoskeleton may not be readily taken up by
astrocytes, or these markers are immediately degraded following
astrocyte absorption.
It’s evident by these recent findings that there is not a
single, “one-size fits all” biomarker suitable for mTBI diagnosis.
The discrepancies across all of these studies call into question
the approach that has been used to identify blood-based
biomarkers for mTBI. The handful of previously identified
biomarkers were derived from studies that screened biofluids
for markers that were known to be associated with severe TBI
pathophysiology (Agoston et al., 2017). This approach has limited
the success for blood-based biomarker diagnostics for mTBI
as the etiology for both conditions are not the same. Using
an unbiased discovery approach, to identify and generate a
panel with multiple blood-based biomarkers that are unique
to mTBI and that accurately represent mTBI pathophysiology
will likely be more efficacious than assessing the sensitivity of a
single biomarker.
The ability to detect neurological biomarkers in biofluids,
other than CSF, and at very low levels has also been challenging
and has further limited the utility of blood-based biomarkers
for mTBI. Moreover, the hesitancy to use exosome cargo as
biomarkers for mTBI is derived from the lack of conclusive
evidence that altered levels of exosome cargo proteins accurately
reflect disease pathogenesis in the CNS. Exosomes have been
shown to act as nano-surrogates of their cells of origin and
possess unique signatures which reflect the status of the cell.
Therefore, using CNS-derived exosomes to quantify levels of
protein biomarkers may be more relevant than free circulating
protein levels in whole blood.
Lastly, we investigated the pathogenetic potential of plasma
NDE and ADE exosome cargo proteins in neuron-like cells.
Work from our lab and others demonstrated that NDEs can
propagate toxic proteins in vivo (Reilly et al., 2017) and induce
toxicity to recipient cells in vitro (Winston et al., 2018). In the
current study, we confirmed that plasma NDEs are toxic to
recipient cells, and we report, for the first time that plasma ADEs
were not toxic to neuron-like cells. Plasma NDEs and ADEs both
contained detectable levels of Aβ42 and p-tau, however, only the
cargo proteins from plasma NDEs of individuals with mTBI were
toxic to neuron-like cells in vitro.
One explanation is ADEs are not easily taken up by neuronal-
like cells. Alternatively, the reduced concentration of Aβ42 and
p-tau in plasma ADEs as compared to plasma NDEs were
insufficient to induce cytotoxicity. It’s also plausible that plasma
ADEs contained anti-inflammatory cytokines and other trophic
molecules that attenuated cytotoxicity in recipient cells. We
hypothesize that NDEs and ADEs have dual neuroprotective
and neurotoxic roles in the CNS. One study reported that
exosomes from astrocytes release inflammatory cytokines,
including IL-1β, to induce an inflammatory response (Kalani
et al., 2014) while another study determined that neuronal
exosomes contain proteins, such as Ndfip1 and Nedd4, which
are thought to play an important role in removing toxic
proteins after injury (Putz et al., 2008). We acknowledge the
limitations of our cytotoxicity assays which include the use
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“neuron-like” cells vs. primary neuronal and astrocyte cultures.
Despite these limitations, we report similar results in two
distinct cell culture model systems. Future studies will include
primary cultured cells from neurons and astrocytes and exosome
treatment in pre-clinical animal models. Lastly, levels of
complement proteins (Winston et al., 2019) and pro- and/or
anti-inflammatory cytokines were not quantified in the current
study, however, that is also future direction. Addressing this in
future studies will provide better insight into the dual role that
plasma exosomes derived from astrocytes may play in mTBI
and other neurodegenerative diseases. Further investigation is
needed to determine how exosomes from different cells mediate
divergent biological processes in the healthy CNS and during
CNS injury and disease.
Additional limitations to the study should also be considered.
This was a male, military sample and thus may not be
generalized to other forms of mTBI in civilians or in women.
Imaging and helmet sensor verification for the injuries was
not available thus case-control selection was based on self-
report, a common problem for military mTBI studies. Indeed,
retrospective self-report is most commonly all that is available
for clinical TBI diagnoses in the Veteran population, and
thus identification of potential biomarkers through exosome
cargo may yield important future clinical applications. Studies
are now ongoing to identify the timecourse of these proteins
following injury and to disentangle if these proteins predict
long-term chronicity and/or comorbidity with other disorders
such as PTSD and neurodegenerative disorders in Veterans that
endorse prior TBI.
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